[go: up one dir, main page]

CL2014001081A1 - Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica. - Google Patents

Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica.

Info

Publication number
CL2014001081A1
CL2014001081A1 CL2014001081A CL2014001081A CL2014001081A1 CL 2014001081 A1 CL2014001081 A1 CL 2014001081A1 CL 2014001081 A CL2014001081 A CL 2014001081A CL 2014001081 A CL2014001081 A CL 2014001081A CL 2014001081 A1 CL2014001081 A1 CL 2014001081A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
antibodies
antibody
vector
host cell
Prior art date
Application number
CL2014001081A
Other languages
English (en)
Inventor
Patrick Garidel
Isaac Craig Henderson
Pamela Klein
Original Assignee
Onclave Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onclave Therapeutics Ltd filed Critical Onclave Therapeutics Ltd
Publication of CL2014001081A1 publication Critical patent/CL2014001081A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CL2014001081A 2011-10-25 2014-04-25 Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica. CL2014001081A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551406P 2011-10-25 2011-10-25

Publications (1)

Publication Number Publication Date
CL2014001081A1 true CL2014001081A1 (es) 2014-11-21

Family

ID=48168501

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014001081A CL2014001081A1 (es) 2011-10-25 2014-04-25 Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica.
CL2017002283A CL2017002283A1 (es) 2011-10-25 2017-09-08 Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017002283A CL2017002283A1 (es) 2011-10-25 2017-09-08 Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)

Country Status (19)

Country Link
US (6) US9089529B2 (es)
EP (2) EP4088736A1 (es)
JP (6) JP6431372B2 (es)
KR (2) KR102276161B1 (es)
CN (2) CN104023743B (es)
AU (4) AU2012328739B2 (es)
BR (1) BR112014009866A2 (es)
CA (1) CA2853112C (es)
CL (2) CL2014001081A1 (es)
CO (1) CO7020867A2 (es)
EA (1) EA037797B1 (es)
HK (1) HK1198689A1 (es)
IL (1) IL232213B (es)
IN (1) IN2014CN03555A (es)
MX (2) MX391043B (es)
PE (2) PE20141413A1 (es)
PH (1) PH12014500904B1 (es)
SG (2) SG11201401360XA (es)
WO (1) WO2013063284A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300048T1 (it) 2011-10-28 2023-03-17 Prothena Biosciences Ltd Anticorpi umanizzati che riconoscono alfa-sinucleina
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
JP6463734B2 (ja) * 2013-05-06 2019-02-06 サノフイＳａｎｏｆｉ 抗体を精製するための連続的多工程法
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2018005967A1 (en) 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis
EP3605294A4 (en) 2017-03-23 2020-02-26 Sony Corporation RADIATION RADIATION DEVICE AND PROJECTOR WITH DETECTION FUNCTION
US11530257B2 (en) 2017-06-29 2022-12-20 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
AU2019240413A1 (en) * 2018-03-23 2020-10-08 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
SG11202108767PA (en) 2019-02-12 2021-09-29 Prothena Biosciences Ltd Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2020178638A1 (en) 2019-03-05 2020-09-10 Prothena Biosciences Limited Methods of treating al amyloidosis
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4601619A1 (en) * 2022-10-12 2025-08-20 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000196A1 (en) 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
JPH06507172A (ja) 1991-04-19 1994-08-11 アフィニティー　バイオテック，インコーポレイテッド 転換可能なミクロエマルジョン処方剤
EP0663826B1 (en) 1991-09-27 1998-12-23 Board Of Regents The University Of Texas System Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
US5334380A (en) 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
EP0621774B1 (en) 1992-01-21 1996-12-18 Sri International Improved process for preparing micronized polypeptide drugs
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
CA2130357A1 (en) 1992-02-18 1993-08-19 Doron Friedman Dry compositions for preparing submicron emulsions
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
NZ262634A (en) 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
ATE317397T1 (de) 1993-11-17 2006-02-15 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO1995025504A1 (en) 1994-03-18 1995-09-28 Pharmavene, Inc. Emulsified drug delivery systems
DE69530196T2 (de) 1994-06-02 2003-11-20 Elan Drug Delivery Ltd Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CZ297431B6 (cs) 1994-08-04 2006-12-13 Quadrant Holdings Cambridge Limited Prostredek obsahující dodávací systém pevné dávkypro prímou aplikaci v pevné forme a zpusob jeho výroby
US5593824A (en) 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
CZ391297A3 (cs) 1995-06-07 1998-05-13 Quadrant Holdings Cambridge Limited Způsob přípravy tenké porovité skelné matrice a prostředek tím získaný
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
USRE38431E1 (en) 1995-12-01 2004-02-17 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9705588D0 (en) 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
ATE511831T1 (de) 1997-04-03 2011-06-15 Elias Hakalehto Verfahren zur herstellung von antikörper enthaltenden gummibärchen
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6692767B2 (en) 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
EP1018345B1 (en) 1998-06-26 2008-12-10 Otsuka Pharmaceutical Co., Ltd. Water soluble dry compositions
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
IL142432A0 (en) 1998-10-05 2002-03-10 Penn State Res Found Compositions and methods for enhancing receptor-mediated cellular internalization
DE59914603D1 (de) 1998-11-13 2008-02-14 Jagotec Ag Multidosis-Trockenpulverinhalator mit Pulverreservoir
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
CA2361424C (en) 1999-02-08 2009-04-28 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
JP2002542183A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 成形可能な乾燥した医薬製剤
BR0010262A (pt) 1999-05-03 2002-01-15 Battelle Memorial Institute Composição para formar um aerossol, processo de preparação e de aerossolização de uma composição, e, dispositivo gerador de aerossol
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
GB9914412D0 (en) 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
CA2396503A1 (en) 1999-12-14 2001-06-21 Jeffrey W. Steaffens Stabilizing diluent for polypeptides and antigens
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
DK1397155T3 (en) 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
PH12012502439A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
US6646394B2 (en) * 2001-07-09 2003-11-11 Nissan Motor Co., Ltd. Control device for plurality of rotating electrical machines
DE60235013D1 (de) * 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
HUE031630T2 (en) 2002-02-27 2017-07-28 Immunex Corp Stabilized TNFR-Fc containing arginine
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
JP2006516084A (ja) * 2002-06-27 2006-06-22 セントカー・インコーポレーテツド Ｃｎｇｈ０００４ポリペプチド、抗体、組成物、方法および使用
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR101130948B1 (ko) 2002-11-01 2012-03-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 건조 공정
CA2504610C (en) 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
UA89350C2 (uk) 2002-12-16 2010-01-25 Дженентек, Інк. Гуманізоване антитіло, що зв'язує людський cd20
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
EP3178492A1 (en) * 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
KR101441358B1 (ko) 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ATE476448T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
SI21639A (sl) 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
ES2376556T3 (es) 2004-03-24 2012-03-14 Abbott Biotherapeutics Corp. Utilización de la anticuerpos anti-alfa5beta1 para inhibir la proliferación de las células cancerosas.
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
GB0409795D0 (en) 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1812062B1 (en) * 2004-10-25 2022-03-09 Merck Sharp & Dohme Corp. Anti-addl antibodies and uses thereof
CA2586074C (en) 2004-11-09 2013-07-23 Novagali Pharma Sa Ophthalmic oil-in-water type emulsion with stable positive zeta potential
US20060124266A1 (en) * 2004-11-23 2006-06-15 Novozymes North America, Inc. Use of cyclodextrins for reducing deposits during paper production
US7879313B1 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8048453B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
US7897585B1 (en) 2005-01-04 2011-03-01 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7919072B1 (en) 2005-01-04 2011-04-05 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7910086B1 (en) 2005-01-04 2011-03-22 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7993625B1 (en) 2005-01-04 2011-08-09 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
TW200640492A (en) 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
KR101280273B1 (ko) 2005-04-18 2013-07-15 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정화된 항-ｂ형 간염 바이러스 (ｈｂｖ) 항체 제형
EP1874818B1 (en) 2005-04-22 2011-04-13 Eli Lilly And Company Tgf beta 1 specific antibodies
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
CN103145841A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
WO2007014073A2 (en) 2005-07-22 2007-02-01 Amgen Inc. Concentrated protein lyophilates, methods, and uses
JP5145241B2 (ja) * 2005-12-12 2013-02-13 エフ．ホフマン−ラ ロシュ アーゲー 可変領域におけるグリコシル化を有するアミロイドβに対する抗体
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
EP2004688B2 (en) 2006-03-23 2014-03-05 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
DE102006030164A1 (de) 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
GB0621707D0 (en) 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
MX2009005414A (es) 2006-12-05 2009-06-01 Crucell Holland Bv Formulaciones liquidas de anticuerpo antirrabico.
AR064220A1 (es) * 2006-12-11 2009-03-18 Hoffmann La Roche Formulacion liofilizada mab abeta
US7883664B2 (en) 2007-06-27 2011-02-08 University Of North Carolina At Charlotte Microwave drying process for vitrification of biologics
US8268354B2 (en) 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
MY171841A (en) 2007-12-21 2019-11-04 Hoffmann La Roche Antibody formulation
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009086539A2 (en) * 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
JP5622725B2 (ja) 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
MX2011002402A (es) 2008-09-19 2011-04-05 Hoffmann La Roche Formulacion de anticuerpo novedosa.
AU2009316592B2 (en) * 2008-11-20 2016-01-07 Genentech, Inc. Therapeutic protein formulations
CN201401081Y (zh) 2009-03-26 2010-02-10 徐谦 一种两折型合页
CN201553504U (zh) * 2009-10-30 2010-08-18 浙江浦江缆索有限公司 一种悬索拉索成圈用120t成圈机
EP3116908B1 (en) * 2014-03-14 2019-06-26 Innate Pharma Humanized kir3dl2 antibodies

Also Published As

Publication number Publication date
EP4088736A1 (en) 2022-11-16
PE20191242A1 (es) 2019-09-16
US9884020B2 (en) 2018-02-06
US20140302021A1 (en) 2014-10-09
HK1198689A1 (en) 2015-05-29
AU2017258950A1 (en) 2017-11-30
MX391043B (es) 2025-03-21
US10517830B2 (en) 2019-12-31
IL232213A0 (en) 2014-06-30
KR20140123475A (ko) 2014-10-22
CO7020867A2 (es) 2014-08-11
AU2020201147A1 (en) 2020-03-05
US20180235887A1 (en) 2018-08-23
PH12014500904B1 (en) 2019-01-18
AU2012328739A1 (en) 2014-04-24
HK1243344A1 (zh) 2018-07-13
AU2022202649B2 (en) 2025-07-03
US20160310430A1 (en) 2016-10-27
BR112014009866A2 (pt) 2018-09-04
SG10201604104PA (en) 2016-07-28
PE20141413A1 (es) 2014-10-25
EP2771029A4 (en) 2015-07-01
IL232213B (en) 2019-03-31
EP2771029A1 (en) 2014-09-03
CN107233569A (zh) 2017-10-10
MX2014004786A (es) 2014-08-21
CA2853112A1 (en) 2013-05-02
JP2018184478A (ja) 2018-11-22
EA201490850A1 (ru) 2015-03-31
EA037797B1 (ru) 2021-05-21
WO2013063284A1 (en) 2013-05-02
JP2017057218A (ja) 2017-03-23
JP2022033254A (ja) 2022-02-28
CN104023743A (zh) 2014-09-03
KR20210003928A (ko) 2021-01-12
MX354988B (es) 2018-03-28
NZ623606A (en) 2015-12-24
PH12014500904A1 (en) 2014-06-09
SG11201401360XA (en) 2014-05-29
AU2022202649A1 (en) 2022-05-12
US20210077407A1 (en) 2021-03-18
CN104023743B (zh) 2017-05-03
KR102276161B1 (ko) 2021-07-14
CL2017002283A1 (es) 2018-05-18
US20130295082A1 (en) 2013-11-07
US9089529B2 (en) 2015-07-28
JP6431372B2 (ja) 2018-11-28
JP2023116817A (ja) 2023-08-22
JP2020063307A (ja) 2020-04-23
IN2014CN03555A (es) 2015-07-03
JP2014530917A (ja) 2014-11-20
AU2012328739B2 (en) 2017-11-30
CN107233569B (zh) 2021-08-31
US20150344555A1 (en) 2015-12-03
CA2853112C (en) 2018-08-21
KR102196009B1 (ko) 2021-01-04

Similar Documents

Publication Publication Date Title
CL2014001081A1 (es) Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica.
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
HUS2000056I1 (hu) ANTI-PD-L1 ellenanyagok és alkalmazásaik
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
CL2013003043A1 (es) Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune.
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
CL2014000958A1 (es) Polipeptidos de anticuerpos que antagonizan cd4ol; acido nucleico que codifica dicho anticuerpo; vector y célula huesped que la comprenden; composicion farmacéutica; uso de dichos polipéptidos para tratar enfermedad inmunitaria.
CO7010785A2 (es) Anticuerpos específicos para trop-2 y sus usos
HRP20190243T1 (hr) Priprema konjugata antitijela majtanzinoida postupkom s jednim korakom
CO6801647A2 (es) Formulación para anticuerpo anti-α4β7
CO6801648A2 (es) Formulación para anticuerpo anti-α4β7
BR112014012624A2 (pt) anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
IL249195B (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
HUE044591T2 (hu) Anti-CD40 antitestek és alkalmazásuk
UY34404A (es) Anticuerpo estable unido a múltiples antígenos
PT3219729T (pt) Anticorpo monoclonal contra interleucina-31
CL2014000888A1 (es) Anticuerpos anti-htra1; acido nucleico que codifica dicho anticuerpo; célula anfitriona; metodo para producir dicho anticuerpo; uso para tratar degeneración macular.
CL2013001975A1 (es) Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta.
CL2014000670A1 (es) Cierre para botellas que comprende una composicion de polietileno bimodal; proceso para la preparacion del cierre; proceso para preparar una composicion de polietileno; y composicion de polietileno bimodal.
BR112015006824A2 (pt) anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
CL2014000204A1 (es) Construcción de unión de antígeno que comprende dos anticuerpos de dominio (dabs) separados por una región fc; metodo para construir dicha construcción.
HRP20180858T1 (hr) Protutijela koja se vežu na ox40 i njihove uporabe
DK3275892T3 (da) Præfusions-rsv-f-antigener
IL231777A0 (en) Antibodies against tl1a and uses thereof